<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00295009</url>
  </required_header>
  <id_info>
    <org_study_id>PDL-07272001</org_study_id>
    <nct_id>NCT00295009</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of Prodisc to Spinal Fusion Surgery</brief_title>
  <acronym>PDL</acronym>
  <official_title>A Multi-Center, Prospective, Randomized, Controlled Clinical Trial Comparing the Safety and Effectiveness of ProDisc to Spinal Fusion Surgery in the Treatment of Discogenic Pain Associated With DDD in the Lumbosacral Spine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synthes USA HQ, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synthes USA HQ, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical investigation is to compare the safety and effectiveness of
      ProDisc total disc replacement to spinal fusion surgery in the treatment of discogenic pain
      associated with DDD in the lumbosacral spine. There will be separate study arms for one and
      two level cases.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Success</measure>
    <time_frame>24 Months</time_frame>
    <description>Overall success was a composite endpoint.
A ProDisc patient was considered an overall success if, and only if, ALL of the following criteria were met:
ODI score improved by at least 15% from baseline;
SF-36 score improved from baseline;
Neurologic parameters maintained or improved from baseline;
No re-operations to modify or remove the implant; and
Independent radiographic review confirmed no migration/subsidence, radiolucency, loss of disc height, loss of range of motion, or boney fusion.
A Fusion patient was a considered to be a success if, and only if, ALL of the following criteria were met:
Same as above
Same as above
Same as above
No re-operations to modify the fusion site or correct a complication with an implant; and
Independent radiographic review confirmed strong evidence of fusion and no motion, visible gaps in fusion mass, loss of disc height, migration/subsidence, implant loosening, halos, or radiolucencies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Success</measure>
    <time_frame>60 Months</time_frame>
    <description>Overall success was a composite endpoint. A ProDisc patient was considered an overall success if, and only if, ALL of the following criteria were met:
ODI score improved by at least 15% from baseline;
SF-36 score improved from baseline;
Neurologic parameters maintained or improved from baseline;
No re-operations required to modify or remove the implant; and
Independent radiographic review confirmed no migration/subsidence, radiolucency, loss of disc height, loss of range of motion, or boney fusion.
A Fusion patient was a considered to be a success if, and only if, ALL of the following criteria were met:
Items numbered 1-3, above; 4. No re-operations required to modify the fusion site or correct a complication with an implant; and 5. Independent radiographic review confirmed strong evidence of fusion and no motion, visible gaps in fusion mass, loss of disc height, migration/subsidence, implant loosening, halos, or radiolucencies</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">852</enrollment>
  <condition>Spinal Diseases</condition>
  <arm_group>
    <arm_group_label>1-Level Fusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spinal fusion at a single lumbar level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1-Level ProDisc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total disc replacement with the ProDisc device at one spinal lumbar level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-Level Fusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spinal fusion at two adjacent lumbar levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-Level ProDisc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total disc replacement with the ProDisc device at two adjacent lumbar levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1-level ProDisc (non-randomized)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total disc replacement with the ProDisc device for non-randomized subjects at one spinal lumbar level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-Level ProDisc (Continued Access)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total disc replacement with the ProDisc device for non-randomized subjects at two spinal lumbar levels (only followed out to 24 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ProDisc</intervention_name>
    <description>Total disc replacement with ProDisc</description>
    <arm_group_label>1-Level ProDisc</arm_group_label>
    <arm_group_label>2-Level ProDisc</arm_group_label>
    <arm_group_label>1-level ProDisc (non-randomized)</arm_group_label>
    <arm_group_label>2-Level ProDisc (Continued Access)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Spinal Fusion</intervention_name>
    <description>A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.</description>
    <arm_group_label>1-Level Fusion</arm_group_label>
    <arm_group_label>2-Level Fusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Degenerative Disc Disease (DDD) in one or two adjacent vertebral levels between L3 and
             S1. Diagnosis of DDD requires: a)Back and/or leg (radicular) pain; and b)Radiographic
             confirmation of any 1 of the following by CT, MRI, discography, plain film,
             myelography and/or flexion/extension films: Instability (greater than or equal to 3mm
             translation or 5Â° angulation); Decreased disc height &gt;2mm; Scarring/thickening of
             annulus fibrosis; Herniated nucleus pulposus; or Vacuum phenomenon.

          -  Age between 18 and 60 years.

          -  Failed at least 6 months of conservative treatment.

          -  Oswestry Low Back Pain Disability Questionnaire score of at least 20/50
             (40%)(Interpreted as moderate/severe disability).

          -  Psychosocially, mentally and physically able to fully comply with this protocol
             including adhering to follow-up schedule and requirements and filling out forms.

          -  Signed informed consent.

        Exclusion Criteria:

          -  No more than 2 vertebral levels may have DDD and all diseased levels, either one or
             two, must be treated.

          -  Patients with involved vertebral endplates dimensionally smaller than 34.5mm in the
             medial-lateral and/or 27mm in the anterior-posterior directions.

          -  Known allergy to titanium, polyethylene, cobalt, chromium, or molybdenum.

          -  Prior fusion surgery at any vertebral level.

          -  Clinically compromised vertebral bodies at the affected level(s) due to current or
             past trauma.

          -  Radiographic confirmation of facet joint disease or degeneration.

          -  Lytic spondylolisthesis or spinal stenosis.

          -  Degenerative spondylolisthesis of grade &gt;1.

          -  Back or leg pain of unknown etiology.

          -  Osteopenia or Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple
             Calculated Osteoporosis Risk Estimation), will be used to screen patients to determine
             if a DEXA scan is required. If DEXA is required, exclusion will be defined as a DEXA
             bone density measured T score less than

          -  1.0. The World Health Organization defines osteoporosis as a DEXA T score less than or
             equal to -2.5.

          -  Paget's disease, osteomalacia or any other metabolic bone disease (excluding
             osteoporosis which is addressed above).

          -  Morbid obesity defined as a body mass index &gt;40 or a weight more than 100 lbs. over
             ideal body weight.

          -  Pregnant or interested in becoming pregnant in the next 3 years.

          -  Active infection - systemic or local.

          -  Taking medication or any drug known to potentially interfere with bone/soft tissue
             healing (e.g., steroids).

          -  Rheumatoid arthritis or other autoimmune disease.

          -  Systemic disease including AIDS, HIV, Hepatitis.

          -  Active malignancy: A patient with a history of any invasive malignancy (except
             non-melanoma skin cancer), unless he/she has been treated with curative intent and
             there has been no clinical signs or symptoms of the malignancy for at least 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2006</study_first_submitted>
  <study_first_submitted_qc>February 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2006</study_first_posted>
  <results_first_submitted>June 18, 2014</results_first_submitted>
  <results_first_submitted_qc>July 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 1, 2014</results_first_posted>
  <disposition_first_submitted>May 6, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 6, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 14, 2013</disposition_first_posted>
  <last_update_submitted>July 31, 2014</last_update_submitted>
  <last_update_submitted_qc>July 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1-Level Fusion</title>
          <description>Circumferential fusion at a single lumbar level.</description>
        </group>
        <group group_id="P2">
          <title>1-Level ProDisc</title>
          <description>Total disc arthroplasty with the ProDisc device at one spinal lumbar level.</description>
        </group>
        <group group_id="P3">
          <title>1-Level ProDisc (Non-Randomized)</title>
          <description>Non-randomized total disc arthroplasty with the ProDisc device at one spinal lumbar level.</description>
        </group>
        <group group_id="P4">
          <title>2-Level Fusion</title>
          <description>Circumferential fusion at two adjacent lumbar levels.</description>
        </group>
        <group group_id="P5">
          <title>2-Level ProDisc</title>
          <description>Total disc arthroplasty with the ProDisc device at two adjacent lumbar levels.</description>
        </group>
        <group group_id="P6">
          <title>2-Level ProDisc (Continued Access)</title>
          <description>Non-randomized total disc arthroplasty with the ProDisc device at two spinal lumbar levels. Continued Access patients only followed out to 24 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="183"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="82"/>
                <participants group_id="P5" count="174"/>
                <participants group_id="P6" count="269"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="72"/>
                <participants group_id="P5" count="165"/>
                <participants group_id="P6" count="259"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 24 Month Analysis</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="148"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="60"/>
                <participants group_id="P5" count="133"/>
                <participants group_id="P6" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52">Completed 60 month visit</participants>
                <participants group_id="P2" count="134">Completed 60 month visit</participants>
                <participants group_id="P3" count="39">Completed 60 month visit</participants>
                <participants group_id="P4" count="57">Completed 60 month visit</participants>
                <participants group_id="P5" count="116">Completed 60 month visit</participants>
                <participants group_id="P6" count="0">Continued Access patients were only followed out to 24 months</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="58"/>
                <participants group_id="P6" count="269"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrolled and treated</population>
      <group_list>
        <group group_id="B1">
          <title>1-Level Fusion</title>
          <description>Circumferential fusion at a single lumbar level.</description>
        </group>
        <group group_id="B2">
          <title>1-Level ProDisc</title>
          <description>Total disc arthroplasty with the ProDisc device at one spinal lumbar level.</description>
        </group>
        <group group_id="B3">
          <title>1-Level ProDisc (Non-randomized)</title>
          <description>Non-randomized total disc arthroplasty with the ProDisc device at one spinal lumbar level.</description>
        </group>
        <group group_id="B4">
          <title>2-Level Fusion</title>
          <description>Circumferential fusion at two adjacent lumbar levels.</description>
        </group>
        <group group_id="B5">
          <title>2-Level ProDisc</title>
          <description>Total disc arthroplasty with the ProDisc device at two adjacent lumbar levels.</description>
        </group>
        <group group_id="B6">
          <title>2-Level ProDisc (Continued Access)</title>
          <description>Non-randomized total disc arthroplasty with the ProDisc device at two spinal lumbar levels. Continued Access patients only followed out to 24 months.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="162"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="72"/>
            <count group_id="B5" value="165"/>
            <count group_id="B6" value="259"/>
            <count group_id="B7" value="788"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.2" spread="7.6"/>
                    <measurement group_id="B2" value="39.6" spread="8.0"/>
                    <measurement group_id="B3" value="37.9" spread="8.0"/>
                    <measurement group_id="B4" value="41.8" spread="7.8"/>
                    <measurement group_id="B5" value="41.8" spread="7.7"/>
                    <measurement group_id="B6" value="40.5" spread="7.4"/>
                    <measurement group_id="B7" value="40.3" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="70"/>
                    <measurement group_id="B6" value="103"/>
                    <measurement group_id="B7" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="95"/>
                    <measurement group_id="B6" value="156"/>
                    <measurement group_id="B7" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="165"/>
                    <measurement group_id="B6" value="259"/>
                    <measurement group_id="B7" value="788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Success</title>
        <description>Overall success was a composite endpoint.
A ProDisc patient was considered an overall success if, and only if, ALL of the following criteria were met:
ODI score improved by at least 15% from baseline;
SF-36 score improved from baseline;
Neurologic parameters maintained or improved from baseline;
No re-operations to modify or remove the implant; and
Independent radiographic review confirmed no migration/subsidence, radiolucency, loss of disc height, loss of range of motion, or boney fusion.
A Fusion patient was a considered to be a success if, and only if, ALL of the following criteria were met:
Same as above
Same as above
Same as above
No re-operations to modify the fusion site or correct a complication with an implant; and
Independent radiographic review confirmed strong evidence of fusion and no motion, visible gaps in fusion mass, loss of disc height, migration/subsidence, implant loosening, halos, or radiolucencies</description>
        <time_frame>24 Months</time_frame>
        <population>Patients who completed all 24 month visit analyses</population>
        <group_list>
          <group group_id="O1">
            <title>1-Level Fusion</title>
            <description>Circumferential fusion at a single lumbar level.</description>
          </group>
          <group group_id="O2">
            <title>1-Level ProDisc</title>
            <description>Total disc arthroplasty with the ProDisc device at one spinal lumbar level.</description>
          </group>
          <group group_id="O3">
            <title>1-Level ProDisc (Non-randomized)</title>
            <description>Non-randomized total disc arthroplasty with the ProDisc device at one spinal lumbar level.</description>
          </group>
          <group group_id="O4">
            <title>2-Level Fusion</title>
            <description>Circumferential fusion at two adjacent lumbar levels.</description>
          </group>
          <group group_id="O5">
            <title>2-Level ProDisc</title>
            <description>Total disc arthroplasty with the ProDisc device at two adjacent lumbar levels.</description>
          </group>
          <group group_id="O6">
            <title>2-Level ProDisc (Continued Access)</title>
            <description>Non-randomized total disc arthroplasty with the ProDisc device at two spinal lumbar levels. Continued Access patients only followed out to 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Success</title>
          <description>Overall success was a composite endpoint.
A ProDisc patient was considered an overall success if, and only if, ALL of the following criteria were met:
ODI score improved by at least 15% from baseline;
SF-36 score improved from baseline;
Neurologic parameters maintained or improved from baseline;
No re-operations to modify or remove the implant; and
Independent radiographic review confirmed no migration/subsidence, radiolucency, loss of disc height, loss of range of motion, or boney fusion.
A Fusion patient was a considered to be a success if, and only if, ALL of the following criteria were met:
Same as above
Same as above
Same as above
No re-operations to modify the fusion site or correct a complication with an implant; and
Independent radiographic review confirmed strong evidence of fusion and no motion, visible gaps in fusion mass, loss of disc height, migration/subsidence, implant loosening, halos, or radiolucencies</description>
          <population>Patients who completed all 24 month visit analyses</population>
          <units>percentage of overall successes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="133"/>
                <count group_id="O6" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1"/>
                    <measurement group_id="O2" value="63.5"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="53.3"/>
                    <measurement group_id="O5" value="59.4"/>
                    <measurement group_id="O6" value="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Success</title>
        <description>Overall success was a composite endpoint. A ProDisc patient was considered an overall success if, and only if, ALL of the following criteria were met:
ODI score improved by at least 15% from baseline;
SF-36 score improved from baseline;
Neurologic parameters maintained or improved from baseline;
No re-operations required to modify or remove the implant; and
Independent radiographic review confirmed no migration/subsidence, radiolucency, loss of disc height, loss of range of motion, or boney fusion.
A Fusion patient was a considered to be a success if, and only if, ALL of the following criteria were met:
Items numbered 1-3, above; 4. No re-operations required to modify the fusion site or correct a complication with an implant; and 5. Independent radiographic review confirmed strong evidence of fusion and no motion, visible gaps in fusion mass, loss of disc height, migration/subsidence, implant loosening, halos, or radiolucencies</description>
        <time_frame>60 Months</time_frame>
        <population>Patients who completed all 60 month visit analyses</population>
        <group_list>
          <group group_id="O1">
            <title>1-Level Fusion</title>
            <description>Circumferential fusion at a single lumbar level.</description>
          </group>
          <group group_id="O2">
            <title>1-Level ProDisc</title>
            <description>Total disc arthroplasty with the ProDisc device at one spinal lumbar level.</description>
          </group>
          <group group_id="O3">
            <title>1-Level ProDisc (Non-randomized)</title>
            <description>Non-randomized total disc arthroplasty with the ProDisc device at one spinal lumbar level.</description>
          </group>
          <group group_id="O4">
            <title>2-Level Fusion</title>
            <description>Circumferential fusion at two adjacent lumbar levels.</description>
          </group>
          <group group_id="O5">
            <title>2-Level ProDisc</title>
            <description>Total disc arthroplasty with the ProDisc device at two adjacent lumbar levels.</description>
          </group>
          <group group_id="O6">
            <title>2-Level ProDisc (Continued Access)</title>
            <description>Non-randomized total disc arthroplasty with the ProDisc device at two spinal lumbar levels. Continued Access patients only followed out to 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Success</title>
          <description>Overall success was a composite endpoint. A ProDisc patient was considered an overall success if, and only if, ALL of the following criteria were met:
ODI score improved by at least 15% from baseline;
SF-36 score improved from baseline;
Neurologic parameters maintained or improved from baseline;
No re-operations required to modify or remove the implant; and
Independent radiographic review confirmed no migration/subsidence, radiolucency, loss of disc height, loss of range of motion, or boney fusion.
A Fusion patient was a considered to be a success if, and only if, ALL of the following criteria were met:
Items numbered 1-3, above; 4. No re-operations required to modify the fusion site or correct a complication with an implant; and 5. Independent radiographic review confirmed strong evidence of fusion and no motion, visible gaps in fusion mass, loss of disc height, migration/subsidence, implant loosening, halos, or radiolucencies</description>
          <population>Patients who completed all 60 month visit analyses</population>
          <units>percentage of overall successes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="116"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="53.7"/>
                    <measurement group_id="O3" value="56.4"/>
                    <measurement group_id="O4" value="50.9"/>
                    <measurement group_id="O5" value="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected at each visit through 60 month follow-up</time_frame>
      <desc>SYNCODE is a company defined medical coding category system for AEs</desc>
      <group_list>
        <group group_id="E1">
          <title>1-Level Fusion</title>
          <description>Circumferential fusion at a single lumbar level.</description>
        </group>
        <group group_id="E2">
          <title>1-Level ProDisc</title>
          <description>Total disc arthroplasty with the ProDisc device at one spinal lumbar level.</description>
        </group>
        <group group_id="E3">
          <title>1-Level ProDisc (Non-Randomized)</title>
          <description>Non-randomized total disc arthroplasty with the ProDisc device at one spinal lumbar level.</description>
        </group>
        <group group_id="E4">
          <title>2-Level Fusion</title>
          <description>Circumferential fusion at two adjacent lumbar levels.</description>
        </group>
        <group group_id="E5">
          <title>2-Level ProDisc</title>
          <description>Total disc arthroplasty with the ProDisc device at two adjacent lumbar levels.</description>
        </group>
        <group group_id="E6">
          <title>2-Level ProDisc (Continued Access)</title>
          <description>Non-randomized total disc arthroplasty with the ProDisc device at two spinal lumbar levels. Continued Access patients only followed out to 24 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SYNCODE</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="38" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Loss</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Additional Surgery Index Level</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Surgery - Adjacent Level</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Surgery - Other</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="162"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E5" events="26" subjects_affected="19" subjects_at_risk="165"/>
                <counts group_id="E6" events="23" subjects_affected="18" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>SYNCODE</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="69" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="153" subjects_at_risk="165"/>
                <counts group_id="E6" subjects_affected="219" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="17" subjects_affected="13" subjects_at_risk="72"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E6" events="12" subjects_affected="12" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E5" events="15" subjects_affected="12" subjects_at_risk="165"/>
                <counts group_id="E6" events="27" subjects_affected="23" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Vascular Injury</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Vessel Damage/Bleeding, Minor</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E4" events="10" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E5" events="18" subjects_affected="15" subjects_at_risk="165"/>
                <counts group_id="E6" events="18" subjects_affected="14" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="36" subjects_affected="25" subjects_at_risk="80"/>
                <counts group_id="E2" events="54" subjects_affected="38" subjects_at_risk="162"/>
                <counts group_id="E3" events="20" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E4" events="49" subjects_affected="28" subjects_at_risk="72"/>
                <counts group_id="E5" events="97" subjects_affected="66" subjects_at_risk="165"/>
                <counts group_id="E6" events="127" subjects_affected="81" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Burning or Dysesthetic Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E6" events="10" subjects_affected="10" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Degenerative Disease Progression</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="162"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Degenerative Disease Progression, Other Lumbar</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E6" events="9" subjects_affected="8" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="15" subjects_affected="13" subjects_at_risk="72"/>
                <counts group_id="E5" events="32" subjects_affected="31" subjects_at_risk="165"/>
                <counts group_id="E6" events="36" subjects_affected="36" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="162"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E5" events="28" subjects_affected="25" subjects_at_risk="165"/>
                <counts group_id="E6" events="34" subjects_affected="31" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E5" events="19" subjects_affected="15" subjects_at_risk="165"/>
                <counts group_id="E6" events="24" subjects_affected="24" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E5" events="23" subjects_affected="22" subjects_at_risk="165"/>
                <counts group_id="E6" events="33" subjects_affected="33" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Numbness Peripheral Nerve or Non-Index Level Related</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E2" events="35" subjects_affected="27" subjects_at_risk="162"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E4" events="20" subjects_affected="15" subjects_at_risk="72"/>
                <counts group_id="E5" events="42" subjects_affected="30" subjects_at_risk="165"/>
                <counts group_id="E6" events="56" subjects_affected="44" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="162"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E4" events="19" subjects_affected="13" subjects_at_risk="72"/>
                <counts group_id="E5" events="36" subjects_affected="27" subjects_at_risk="165"/>
                <counts group_id="E6" events="24" subjects_affected="23" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" events="48" subjects_affected="34" subjects_at_risk="80"/>
                <counts group_id="E2" events="129" subjects_affected="85" subjects_at_risk="162"/>
                <counts group_id="E3" events="30" subjects_affected="23" subjects_at_risk="50"/>
                <counts group_id="E4" events="55" subjects_affected="42" subjects_at_risk="72"/>
                <counts group_id="E5" events="97" subjects_affected="67" subjects_at_risk="165"/>
                <counts group_id="E6" events="107" subjects_affected="84" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pain - Back and Lower Extremities</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="80"/>
                <counts group_id="E2" events="54" subjects_affected="44" subjects_at_risk="162"/>
                <counts group_id="E3" events="23" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E4" events="27" subjects_affected="23" subjects_at_risk="72"/>
                <counts group_id="E5" events="63" subjects_affected="46" subjects_at_risk="165"/>
                <counts group_id="E6" events="51" subjects_affected="43" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pain - Back and Lower Extremities with Numbness at Index Level</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pain - Back and Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E5" events="15" subjects_affected="15" subjects_at_risk="165"/>
                <counts group_id="E6" events="23" subjects_affected="22" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pain - Incision Site</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E5" events="19" subjects_affected="19" subjects_at_risk="165"/>
                <counts group_id="E6" events="21" subjects_affected="21" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pain - Lower Extremities</sub_title>
                <counts group_id="E1" events="30" subjects_affected="20" subjects_at_risk="80"/>
                <counts group_id="E2" events="75" subjects_affected="51" subjects_at_risk="162"/>
                <counts group_id="E3" events="26" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E4" events="43" subjects_affected="30" subjects_at_risk="72"/>
                <counts group_id="E5" events="83" subjects_affected="61" subjects_at_risk="165"/>
                <counts group_id="E6" events="110" subjects_affected="85" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pain - Lower Extremities with Numbness at Index Level</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E6" events="16" subjects_affected="15" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pain Other (Not back, hip, leg)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="80"/>
                <counts group_id="E2" events="66" subjects_affected="46" subjects_at_risk="162"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E4" events="24" subjects_affected="16" subjects_at_risk="72"/>
                <counts group_id="E5" events="38" subjects_affected="32" subjects_at_risk="165"/>
                <counts group_id="E6" events="38" subjects_affected="37" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pseudoarthrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Wound Issues - Other</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E5" events="17" subjects_affected="15" subjects_at_risk="165"/>
                <counts group_id="E6" events="26" subjects_affected="23" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other non-wound related</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="165"/>
                <counts group_id="E6" events="13" subjects_affected="13" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Infection - Superficial Wound with Incision Site Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Infection, Not Index Level Related</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Migration Not Requiring Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscoloskeletal Spasms - Back</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E5" events="24" subjects_affected="21" subjects_at_risk="165"/>
                <counts group_id="E6" events="30" subjects_affected="27" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Spasms - Leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="165"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Spasm</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Non-Specific Musculoskeletal Spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E6" events="16" subjects_affected="15" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Other Musculoskeletal</sub_title>
                <counts group_id="E1" events="26" subjects_affected="19" subjects_at_risk="80"/>
                <counts group_id="E2" events="40" subjects_affected="26" subjects_at_risk="162"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="72"/>
                <counts group_id="E5" events="24" subjects_affected="20" subjects_at_risk="165"/>
                <counts group_id="E6" events="32" subjects_affected="30" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E2" events="46" subjects_affected="33" subjects_at_risk="162"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="162"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E4" events="17" subjects_affected="12" subjects_at_risk="72"/>
                <counts group_id="E5" events="38" subjects_affected="31" subjects_at_risk="165"/>
                <counts group_id="E6" events="33" subjects_affected="32" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E5" events="23" subjects_affected="22" subjects_at_risk="165"/>
                <counts group_id="E6" events="22" subjects_affected="21" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatological</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E5" events="8" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Dermatological or Drug Allergy</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="162"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Incision Site Related</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="80"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E6" events="14" subjects_affected="14" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Additional Surgery Index Level</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Surgery - Index Level (Revision)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Surgery - Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E5" events="47" subjects_affected="34" subjects_at_risk="165"/>
                <counts group_id="E6" events="28" subjects_affected="27" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Erin Prifogle</name_or_title>
      <organization>DePuy Synthes</organization>
      <phone>508-977-6451</phone>
      <email>eprifog1@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

